Z. Diamant (Lund, Sweden), P. Sivapalan (Gentofte, Denmark)
Effect of once daily (o.d.) mometasone/indacaterol/glycopyrronium (MF/IND/GLY) vs o.d. MF/IND and twice daily (b.i.d.) fluticasone/salmeterol (FLU/SAL) with respect to age, age at asthma-onset and BMI at baseline: Subgroup analysis from IRIDIUM study
H. Kerstjens (Groningen, Netherlands), D. Lawrence (Basel, Switzerland), K. Mezzi (Basel, Switzerland), D. Brittain (Basel, Switzerland), X. Jaumont (Basel, Switzerland), K. Chapman (Toronto, Canada)
|   |
A window of opportunity to prevent exacerbations in intermittent and mild persistent asthma
M. Lanz (Coral Gables, United States), M. Pollack (Wilmington, United States), I. Gilbert (Wilmington, United States), H. Gandhi (Wilmington, United States), J. Tkacz (Washington DC, United States), N. Lugogo (Ann Arbor, United States)
| |
Predictors of treatment response to high-dose ICS/LABA or medium-dose ICS/LABA+LAMA in asthma patients - TAILOR study
K. Verhamme (Rotterdam, Netherlands), M. De Ridder (Rotterdam, Netherlands), P. Rijnbeek (Rotterdam, Netherlands), M. Mosseveld (Rotterdam, Netherlands), L. Pedersen (Aarhus, Denmark), E. Marconi (Florence, Italy), F. Lapi (Florence, Italy), C. Tan (Oxford, United Kingdom), A. Delmestri (Oxford, United Kingdom), D. Prieto-Alhambra (Oxford, United Kingdom), D. Prieto-Alhambra (Rotterdam, Netherlands), E. Nudo (Parma, Italy), G. Brusselle (Ghent, Belgium)
| |
SABA-free asthma management challenged by refer id asthma questionnaire.
L. Nannini (Rosario, Argentina), N. Brandan (Rosario, Argentina), O. Fernandez (Rosario, Argentina), G. Chirino (Buenos Aires, Argentina), N. Zuccarino (Buenos Aires, Argentina), F. Rovira (Buenos Aires, Argentina)
| |
Short and longer-term effects of tailored pulmonary rehabilitation for difficult-to-control asthma associated with elevated body mass index
C. Ricketts (Glasgow (Glasgow), United Kingdom), F. Steffensen (Glasgow, United Kingdom), D. Buchan (Hamilton, United Kingdom), R. Chaudhuri (Glasgow, United Kingdom), D. Cowan (Glasgow (Glasgow), United Kingdom)
| |
Efficacy of once-daily medium- or high-dose mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus twice-daily high-dose fluticasone/salmeterol (FLU/SAL) to control nocturnal symptoms in patients (pts) with inadequately controlled asthma
K. Chapman (Toronto (ON), Canada), R. Van-Zyl Smit (Cape Town, South Africa), K. Mezzi (Basel, Switzerland), D. Brittain (Basel, Switzerland), H. Kerstjens (Groningen, Netherlands)
| |
Efficacy of once-daily (o.d.) indacaterol/glycopyrronium/mometasone (IND/GLY/MF) vs free combination of twice-daily salmeterol/fluticasone (SAL/FLU) & o.d. tiotropium with respect to age, age at asthma-onset & BMI at baseline: ARGON subgroup analysis
R. Van Zyl-Smit (Cape Town, South Africa), D. Lawrence (Basel, Switzerland), K. Mezzi (Basel, Switzerland), D. Brittain (Basel, Switzerland), X. Jaumont (Basel, Switzerland), C. Gessner (Leipzig, Germany)
| |
Asthma patient adherence to biologic and non-biologic treatments
M. Tan (London, United Kingdom), K. Kueh (Kuala Lumpur, Malaysia)
| |
Medication adherence and asthma control with once-daily indacaterol/glycopyrronium/mometasone (IND/GLY/MF) Breezhaler digital companion: interim analysis from Europe
H. Woehrle (Ulm, Germany), P. Mastoridis (East Hanover, NJ, United States), D. A Stempel (San Francisco, CA, United States), L. Kaye (San Francisco, CA, United States), V. Vuong (San Francisco, CA, United States), K. Mezzi (Basel, Switzerland)
| |
Medication adherence and asthma control with once-daily indacaterol/glycopyrronium/mometasone (IND/GLY/MF) Breezhaler digital companion: interim analysis from Japan and Germany
H. Woehrle (Ulm, Germany), P. Mastoridis (East Hanover, NJ, United States), D. A Stempel (San Francisco, CA, United States), L. Kaye (San Francisco, CA, United States), V. Vuong (San Francisco, CA, United States), K. Mezzi (Basel, Switzerland)
| |
Efficacy of indacaterol/glycopyrronium/mometasone (IND/GLY/MF) vs free combination of salmeterol/fluticasone (SAL/FLU) & tiotropium (TIO) in patients with uncontrolled asthma on prior LABA/ICS high-dose (GINA step 5): Results from ARGON study
C. Gessner (Leipzig, Germany), D. Lawrence (Basel, Switzerland), K. Mezzi (Basel, Switzerland), D. Brittain (Basel, Switzerland), R. Van-Zyl Smit (CapeTown, South Africa)
| |
TriOptimize X: Improved adherence by extrafine single-inhaler triple therapy in real-world
C. Criee (Bovenden, Germany), F. Trinkmann (Heidelberg, Germany), S. Güldenring (Hamburg, Germany), N. Loeper (Hamburg, Germany), V. Bogoevska (Hamburg, Germany), C. Gessner (Leipzig, Germany)
| |
Airway hyperresponsiveness in uncontrolled severe eosinophilic asthma with anti-IL5ra
R. Chan (Dundee, United Kingdom), C. Kuo (Dundee, United Kingdom), S. Jabbal (Dundee, United Kingdom), C. Smith (Dundee, United Kingdom), B. Lipworth (Dundee, United Kingdom)
| |
Bronchodilator responsiveness testing with inhaled budesonide/formoterol in asthma.
L. Nannini (Rosario, Argentina), N. Neumayer (Baigorr, Argentina), N. Brandan (Baigorr, Argentina), O. Fernandez (Baigorr, Argentina)
| |
Oral corticosteroid-related morbidity and mortality in asthma - a Danish nationwide cohort study
I. Skov (Odense, Denmark), H. Madsen (Svendborg, Denmark), D. Henriksen (Odense, Denmark), J. Andersen (Odense, Denmark), A. Pottegård (Odense, Denmark), J. Davidsen (Odense, Denmark)
| |
Determinants of type of step-up treatment following medium-dose ICS/LABA in asthma patients - TAILOR study
K. Verhamme (Rotterdam, Netherlands), M. De Ridder (Rotterdam, Netherlands), P. Rijnbeek (Rotterdam, Netherlands), M. Mosseveld (Rotterdam, Netherlands), L. Pedersen (Aarhus, Denmark), F. Lapi (Florence, Italy), E. Marconi (Florence, Italy), C. Tan (Oxford, United Kingdom), A. Delmestri (Oxford, United Kingdom), D. Prieto-Alhambra (Oxford, United Kingdom), D. Prieto-Alhambra (Rotterdam, Netherlands), E. Nudo (Parma, Italy), G. Brusselle (Ghent, Belgium)
| |
Early lung function and asthma control test score after different biological therapy in severe asthmatics patients in real-life
M. Navarrete Rouco (Barcelona (Barcelona), Spain), C. Cumpli (Barcelona (Barcelona), Spain), E. Hernández (Barcelona (Barcelona), Spain), J. Martínez-Llorens (Barcelona (Barcelona), Spain), N. Carballo (Barcelona (Barcelona), Spain), J. González-García (Barcelona (Barcelona), Spain), P. Ausin (Barcelona (Barcelona), Spain)
| |
Once-daily Inhaled therapy and peak flowmetry: How effective in improving adherence and control of Asthma
P. Dadhich (Ajmer, India)
| |